(Q40468558)

English

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

scientific article published on 15 March 2006

Statements

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. (English)
Scott Kitchener
Dennis Morrison
Richard Nichols
Niranjan Kanesa-Thasan
Philip Bedford
Marie-Jose Quentin-Millet

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit